Back to MW Marshall Wace, LLP

PTGXPTGX

Showing 7 of 21 quarters

Position history for MWMarshall Wace, LLP's holdings in Protagonist Therapeutics, Inc.

Yes. Marshall Wace holds 109,017 shares of PTGX, worth $13.4M, as of its Q2 2026 13F filing. It reduced the position by 519,058 shares (-82.6%) from Q1 2026. Marshall Wace has held PTGX since Q3 2025, across 4 quarterly 13F filings.

Current Value

$13.4M

Current Shares

109,017

Total Value Change

-$828,482

Total Shares Change

-206,356

Quarter-by-Quarter History
QuarterActionSharesChangeValueWeightPriceConviction
2026-Q2
Latest
Decreased
109,017
-82.6%
$13.4M0.0%$122.58
0
2026-Q1
Decreased
628,075
-38.7%
$66.2M0.1%$105.40
0
2025-Q4
Decreased
1M
-5.6%
$89.5M0.1%$87.34
0
2025-Q3
New
1.1M
—
$72.1M0.1%$66.43
41
2025-Q1
Exited
0
-100.0%
$00.0%$48.36
0
2024-Q4
Decreased
19,716
-93.8%
$761,0380.0%$38.60
0
2024-Q3
Decreased
315,373
-44.9%
$14.2M0.0%$45.00
0

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used